Retatrutide hmoov

Retatrutide yog triple agonist peptide tsom glucagon-zoo li peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), thiab glucagon receptor (GCGR). Nrog nws cov txiaj ntsig ntau ntawm kev txo cov ntshav qab zib, txo qhov hnyav, thiab txhim kho cov metabolism, nws tuav cov lus cog tseg ua cov khoom tseem ceeb hauv kev kho cov kab mob metabolic.

YTBIO muab Retatrutide nrog98% purity. Peb muab cov ntim ntim tau yooj yim los ntawm milligram mus rau gram theem, txhawb kev pabcuam customized, thiab muab Daim Ntawv Pov Thawj Ua Haujlwm tiav (COA) thiab MSDS cov ntaub ntawv nrog txhua qhov khoom xa tuaj. Thov hu rau peb rau cov qauv kuaj.

Txhawm rau nkag siab txog cov txheej txheem ntawm kev ua ntawm Retatrutide, nws yog thawj zaug uas yuav tsum paub tias tus receptor agonist yog dab tsi. Cia peb pib nrog lub ntsiab lus ceev ntawm receptors; lawv yog cov protein molecules uas muaj nyob rau saum npoo ntawm peb cov pores. Cov receptors no tau txais cov cim los ntawm sab nraud ntawm tes; Cov teeb liab tuaj yeem los ntawm neurotransmitter, tshuaj hormones, lossis tshuaj. Cov tshuaj no tuaj yeem khi rau cov receptors thiab xa cov lus rau peb lub hlwb. Thaum peb lub hlwb tau txais cov lus, lawv qhib thiab ua haujlwm. Piv txwv li, qab los noj mov-cov tshuaj hormones xws li ghrelin los yog leptin hormones txhawb peb qab los noj mov los yog qhia rau peb cov hlwb paub tias peb puv tom qab noj mov, feem. Yog tsis muaj receptors, peb lub hlwb tsis tuaj yeem txais cov ntaub ntawv no.

Cov txheej txheem ntawm kev txiav txim ntawm retatrutide yog ua raws li kev ua haujlwm ib txhij ntawm peb cov txheej txheem metabolic receptors: GLP-1R, GIPR, thiab GCGR. GLP-1R kev ua kom muaj zog txhawb kev tsim cov tshuaj insulin thiab ua rau lub plab zom mov qeeb hauv cov piam thaj-raws li, ua tiav kev tswj cov ntshav qabzib; Kev ua kom GIPR txhim kho cov ntaub so ntswg peripheral insulin rhiab heev thiab txhawb nqa cov piam thaj los ntawm cov ntaub so ntswg adipose; thiab GCGR kev ua kom ncaj qha koom nrog kev siv hluav taws xob los ntawm kev tswj hwm cov piam thaj hauv siab thiab txhawb nqa lipid tawg. Kev sib koom ua ke ntawm peb lub hom phiaj no ua rau retatrutide ua kom pom cov txiaj ntsig zoo metabolic hauv kev kho mob uas dhau ntawm cov tshuaj ib leeg lossis ob lub hom phiaj.

Hormonal cov lus teb rau kev noj zaub mov noj yog qhov tseem ceeb ntawm kev tswj cov metabolism. Qhov zoo tshaj plaws -paub yog insulin secretion nyob rau hauv cov lus teb rau nce postprandial qabzib los yog amino acid theem, txhawb cov as-ham cia thiab tswj cov ntshav qab zib ib txwm. Tsis tas li ntawd, lub plab zom mov cov lus teb rau kev noj zaub mov ntxiv ua kom cov tshuaj insulin ntau ntxiv (piv txwv li, "cov nyhuv incretin" kho los ntawm glucagon{5}}zoo li peptide-1 [GLP-1] thiab cov piam thaj-dependent insulinotropic polypeptide [GIP]) los tswj cov yam ntxwv ntawm satiety, noj zaub mov kom tsawg, thiab noj mov metabolism. Glucagon (GCG) muaj cov nyhuv catabolic muaj zog uas txhawb nqa lipolysis, txo cov zaub mov noj, ua rau lub plab zom mov qeeb, thiab nce kev siv zog. Retaglutide tuaj yeem qhib GLP-1, GIP, thiab GCG receptors, thiab triple G agonists yog qhov theoretically superior rau ib leeg lossis dual agonists hauv kev txo qhov hnyav, txo qis hepatic steatosis, thiab normalizing ntshav qab zib.

In a clinical trial of 388 participants with a BMI >30 lossis BMI 27 txog 30 uas muaj yam tsawg kawg ib qho hnyav- cuam tshuam, koob tshuaj ntau tshaj ntawm retaglutide ua rau qhov hnyav nruab nrab ntawm 18% ntawm 24 lub lis piam thiab 24% ntawm 48 lub lis piam, piv nrog qhov hnyav nruab nrab ntawm 2% ntawm ob lub sij hawm cov ntsiab lus rau cov placebo pawg. Ntawm qhov koob tshuaj ntau tshaj, 26% ntawm cov neeg koom tau poob ntau dua 30% ntawm lawv lub cev qhov hnyav ntawm 48 lub lis piam, nrog kev poob qis hauv cov neeg koom nrog BMI ntau dua 35. Ntau qhov kev ntsuas ntawm cardiometabolic kev pheej hmoo tau txhim kho, suav nrog ntshav siab thiab qib glycated hemoglobin, yoo mov qabzib, insulin, tag nrho thiab qis dua -cov roj cholesterol lipoproteinsity, tripoproteinsity thiab qis.

Cov txiaj ntsig ntawm Retaglutide kev sim tshuaj

Cov txiaj ntsig ntawm triple agonist kuj txuas ntxiv mus rau kev kho mob ntawm cov kab mob uas tsis yog-coholic fatty siab. Hauv ib pawg ntawm 98 tus neeg koom nrog cov kab mob uas tsis yog-coholic fatty siab nyob rau hauv qhov kev sim, 90% ntawm cov neeg koom nrog cov tshuaj ntau tshaj ntawm cov tshuaj retaglutide tau ua rau lub siab muaj roj ntau.
Vim tias kev rog rog yog kab mob ntev (zoo ib yam li ntshav siab), nws yog ib qho tsim nyog los tswj nws nrog kev kho mob ntev -.

YTBIO cov khoom sivRetatrutide hmoovmuaj qhov zoo.Professional Retatrutide lwm tus.Lub tuam txhab tau tsim nyob rau hauv 2014 thiab muaj ntau xyoo ntawm kev paub hauv R & D thiab ntau lawm. Peb tau cog lus rau R & D, ntau lawm thiab muag khoom raw khoom rau kev noj qab haus huv kev lag luam nyob rau hauv lub xyoo pua 21st. Cov ntawv pov thawj tau txais tam sim no suav nrog ISO9001, ISO22000, HALAL, KOSHER, HACCP, FDA, thiab lwm yam. Peb ib txwm tuav cov kev xav tau siab tshaj plaws ntawm cov khoom zoo.

Cim npe nrov: Tuam Tshoj Retatrutide hmoov manufacturers, lwm tus neeg, Hoobkas